Celecoxib

Evidence Level: L5

Predicted Indications: 7

Celecoxib

Pharmacist Assessment Report

Celecoxib: From Inflammatory Arthritis to Acromesomelic Dysplasia, Hunter-Thompson Type

One-Sentence Summary

Celecoxib is a COX-2 inhibitor (an anti-inflammatory painkiller) originally used for arthritis, including rheumatoid arthritis, ankylosing spondylitis, osteoarthritis and juvenile idiopathic arthritis. The TxGNN model predicts it may be effective for acromesomelic dysplasia, Hunter-Thompson type, a rare genetic skeletal disorder. The score is high, but there are 0 clinical trials and 0 publications supporting this prediction, so it is a model-only signal.

Quick Overview

Item	Content
Original Indication	Rheumatoid arthritis, ankylosing spondylitis, osteoarthritis, juvenile idiopathic arthritis (the Indian licence records contain no approved-indication text, so this comes from the drug’s known indication data)
Predicted New Indication	Acromesomelic dysplasia, Hunter-Thompson type
TxGNN Prediction Score	0.9988
Evidence Level	L5
India Market Status	Listed in a compiled Indian medicine price dataset (at least 20) – CDSCO approval status is not included in this data
Number of Listed Products	at least 20
Recommended Decision	Hold

Why is This Prediction Reasonable?

Currently, detailed mechanism of action data is not available in the data compiled for this report. Celecoxib is known as a selective COX-2 inhibitor that reduces prostaglandin-mediated inflammation and pain. It is proven in several inflammatory arthropathies.

Acromesomelic dysplasia, Hunter-Thompson type, is a rare genetic skeletal dysplasia caused by loss-of-function variants in the CDMP1/GDF5 gene. The underlying defect is in BMP/GDF signalling, which controls limb bone growth. COX-2 inhibition is not known to act on this pathway, and no clear mechanistic link was identified.

The high score most likely reflects the model’s network proximity between celecoxib and arthropathy or skeletal phenotypes, not a biological rationale. The prediction should be treated as a hypothesis only.

Clinical Trial Evidence

Currently no related clinical trials registered.

Literature Evidence

Currently no related literature available.

India Market Information

Celecoxib is marketed in India as a single-ingredient oral product, with 20 valid registrations and none cancelled. The data compiled for this report do not include approved-indication text for these licences. Five main registrations:

Authorization Number	Product Name	Dosage Form	Manufacturer
206039	Sionara 200mg Capsule	Strip of 10 capsules	Alembic Pharmaceuticals Ltd
109396	Icel 200mg Capsule	Strip of 10 capsules	Zydus Cadila
39656	Celicx 200 Capsule	Strip of 10 capsules	Goldenlad Pharmaceutical Pvt Ltd
34934	Coxib 90mg Tablet	Strip of 10 tablets	Micro Labs Ltd
189254	Revibra 200mg Capsule	Strip of 10 capsules	Dr Reddy’s Laboratories Ltd

Safety Considerations

Contraindication signals from the knowledge graph (these come from drug-disease relationships, not package insert text): hypertension, kidney disease, liver disease, gallbladder disease, congestive heart failure, active peptic ulcer disease, asthma, stroke and other cerebrovascular disorders, myocardial infarction and other cardiovascular or heart disease, anaemia, hemoglobinopathy, and substance abuse/dependence.
Drug Interactions: 646 interactions are recorded, which is a large burden.
- Major: eliglustat.
- Moderate (examples): hydrocortisone, metformin, sulfonylureas (glimepiride, glipizide, glyburide, chlorpropamide, acetohexamide), nateglinide, exenatide, cimetidine, levofloxacin, metronidazole, kanamycin, naltrexone, mesalazine, balsalazide, olsalazine, fenfluramine, dexfenfluramine.

Please refer to the package insert for label warnings and contraindications.

Conclusion and Next Steps

Decision: Hold

Rationale: The prediction rests only on a score from the TxGNN model (deep learning), which may reflect similarities the model learned between related diseases, not biological evidence. There are no trials or publications, and no plausible mechanism links COX-2 inhibition to the GDF5-related skeletal defect. The safety profile (cardiovascular, gastrointestinal and renal signals) offers no offsetting benefit for this indication.

To proceed, the following is needed:

Mechanistic or preclinical evidence that COX-2 inhibition affects GDF5/BMP signalling or limb growth in this disorder
Detailed mechanism of action data for celecoxib
Package insert warnings and contraindications from the Indian labels
A safety assessment relevant to the likely patient population, including paediatric use

Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.